As Sanofi’s Lantus has led the basal insulin field and Merck’s Januvia, the DPP-4 class, Novo Nordisk’s Victoza has been the dominant GLP-1 drug for years. Lately, however, its market share is on the wane, thanks to new rivals, particularly Eli Lilly’s Trulicity.
